Published in J Cancer Res Clin Oncol on November 30, 2014
Novel EGFR-specific immunotoxins based on panitumumab and cetuximab show in vitro and ex vivo activity against different tumor entities. J Cancer Res Clin Oncol (2015) 0.79
Immunotoxin Therapies for the Treatment of Epidermal Growth Factor Receptor-Dependent Cancers. Toxins (Basel) (2016) 0.78
Head and neck rhabdomyosarcoma: follow-up results of four cases and review of the literature. Int J Clin Exp Pathol (2015) 0.75
Generation of an artificial human B cell line test system using Transpo-mAbTM technology to evaluate the therapeutic efficacy of novel antigen-specific fusion proteins. PLoS One (2017) 0.75
Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature (1970) 1528.65
The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP. Proc Natl Acad Sci U S A (2008) 8.08
Fusion gene-negative alveolar rhabdomyosarcoma is clinically and molecularly indistinguishable from embryonal rhabdomyosarcoma. J Clin Oncol (2010) 4.93
Ligand-targeted therapeutics in anticancer therapy. Nat Rev Cancer (2002) 3.75
The quest to overcome resistance to EGFR-targeted therapies in cancer. Nat Med (2013) 3.20
Rapid tumor penetration of a single-chain Fv and comparison with other immunoglobulin forms. Cancer Res (1992) 2.83
Immunotoxin treatment of cancer. Annu Rev Med (2007) 2.36
PAX3/FOXO1 fusion gene status is the key prognostic molecular marker in rhabdomyosarcoma and significantly improves current risk stratification. J Clin Oncol (2012) 2.29
Targeting the epidermal growth factor receptor for cancer therapy. J Clin Oncol (2002) 2.26
Molecular classification of rhabdomyosarcoma--genotypic and phenotypic determinants of diagnosis: a report from the Children's Oncology Group. Am J Pathol (2009) 2.14
Recombinant toxins as novel therapeutic agents. Annu Rev Biochem (1992) 2.05
Immunotoxins for targeted cancer therapy. AAPS J (2006) 1.86
Molecular mechanisms of resistance to therapies targeting the epidermal growth factor receptor. Clin Cancer Res (2005) 1.83
Targeting the ERBB family in cancer: couples therapy. Nat Rev Cancer (2013) 1.72
A guide to taming a toxin--recombinant immunotoxins constructed from Pseudomonas exotoxin A for the treatment of cancer. FEBS J (2011) 1.70
scFv antibody: principles and clinical application. Clin Dev Immunol (2012) 1.64
Sym004: a novel synergistic anti-epidermal growth factor receptor antibody mixture with superior anticancer efficacy. Cancer Res (2010) 1.59
Epidermal growth factor receptor expression identifies functionally and molecularly distinct tumor-initiating cells in human glioblastoma multiforme and is required for gliomagenesis. Cancer Res (2010) 1.59
EGFR tyrosine kinase inhibitors in lung cancer: an evolving story. Annu Rev Med (2008) 1.46
Pharmacokinetics and biodistribution of genetically-engineered antibodies. Q J Nucl Med (1998) 1.41
Recombinant toxins for cancer treatment. Science (1991) 1.36
Immunotoxins for leukemia. Blood (2014) 1.33
Rational identification of an optimal antibody mixture for targeting the epidermal growth factor receptor. MAbs (2011) 1.29
Binding of an antagonistic monoclonal antibody to an intact and fragmented EGF-receptor polypeptide. Arch Biochem Biophys (1987) 1.29
Epidermal growth factor receptor targeting in cancer: a review of trends and strategies. Biomaterials (2013) 1.28
Recurrent t(2;2) and t(2;8) translocations in rhabdomyosarcoma without the canonical PAX-FOXO1 fuse PAX3 to members of the nuclear receptor transcriptional coactivator family. Genes Chromosomes Cancer (2010) 1.25
Subtype and prognostic classification of rhabdomyosarcoma by immunohistochemistry. J Clin Oncol (2006) 1.25
CD133 positive embryonal rhabdomyosarcoma stem-like cell population is enriched in rhabdospheres. PLoS One (2011) 1.22
Compatible-solute-supported periplasmic expression of functional recombinant proteins under stress conditions. Appl Environ Microbiol (2000) 1.17
Expression of receptor tyrosine kinases and apoptotic molecules in rhabdomyosarcoma: correlation with overall survival in 105 patients. Cancer (2007) 1.15
Molecular classification of soft tissue sarcomas and its clinical applications. Int J Clin Exp Pathol (2010) 1.15
Immunotoxins: the role of the toxin. Toxins (Basel) (2013) 1.13
Nuclear EGFR shuttling induced by ionizing radiation is regulated by phosphorylation at residue Thr654. FEBS Lett (2010) 1.10
Enhanced EGFR inhibition and distinct epitope recognition by EGFR antagonistic mAbs C225 and 425. Cancer Biol Ther (2008) 1.06
Phosphorylation profiles of protein kinases in alveolar and embryonal rhabdomyosarcoma. Mod Pathol (2007) 1.05
Prospects of bacterial and plant protein-based immunotoxins for treatment of cancer. Cancer Genomics Proteomics (2014) 1.04
Granzyme B-H22(scFv), a human immunotoxin targeting CD64 in acute myeloid leukemia of monocytic subtypes. Mol Cancer Ther (2008) 1.03
Targeted delivery and enhanced cytotoxicity of cetuximab-saporin by photochemical internalization in EGFR-positive cancer cells. Mol Pharm (2007) 0.99
Expression and genomic status of EGFR and ErbB-2 in alveolar and embryonal rhabdomyosarcoma. Mod Pathol (2006) 0.98
Secretion of functional anti-CD30-angiogenin immunotoxins into the supernatant of transfected 293T-cells. Protein Expr Purif (2003) 0.96
The first constant domain (C(H)1 and C(L)) of an antibody used as heterodimerization domain for bispecific miniantibodies. FEBS Lett (1998) 0.94
Site-specific, covalent labeling of recombinant antibody fragments via fusion to an engineered version of 6-O-alkylguanine DNA alkyltransferase. Bioconjug Chem (2009) 0.93
Microtubule-associated protein tau facilitates the targeted killing of proliferating cancer cells in vitro and in a xenograft mouse tumour model in vivo. Br J Cancer (2013) 0.92
Rhabdomyosarcoma in adolescents: a report from the AIEOP Soft Tissue Sarcoma Committee. Cancer (2011) 0.92
Engineering and biological characterization of VB6-845, an anti-EpCAM immunotoxin containing a T-cell epitope-depleted variant of the plant toxin bouganin. J Immunother (2009) 0.91
Recombinant CD64-specific single chain immunotoxin exhibits specific cytotoxicity against acute myeloid leukemia cells. Cancer Res (2003) 0.90
What is new in the biology and treatment of pediatric rhabdomyosarcoma? Curr Opin Pediatr (2014) 0.89
Recombinant antibody toxins specific for ErbB2 and EGF receptor inhibit the in vitro growth of human head and neck cancer cells and cause rapid tumor regression in vivo. Int J Cancer (2000) 0.88
Antisense epidermal growth factor receptor transfection impairs the proliferative ability of human rhabdomyosarcoma cells. Cancer Res (1996) 0.88
Eradication of minimal disease in severe combined immunodeficient mice with disseminated Daudi lymphoma using chemotherapy and an immunotoxin cocktail. Blood (1994) 0.87
Advances in therapy for pediatric sarcomas. Curr Oncol Rep (2014) 0.87
In vivo imaging of immunotoxin treatment using Katushka-transfected A-431 cells in a murine xenograft tumour model. Cancer Immunol Immunother (2012) 0.86
Recombinant anti-EGFR immunotoxin 425(scFv)-ETA' demonstrates anti-tumor activity against disseminated human pancreatic cancer in nude mice. Int J Mol Med (2005) 0.86
Synergistic antitumor activity of anti-CD25 recombinant immunotoxin LMB-2 with chemotherapy. Clin Cancer Res (2011) 0.85
Rhabdomyosarcomas: an overview on the experimental animal models. J Cell Mol Med (2012) 0.84
The combined use of an immunotoxin and a radioimmunoconjugate to treat disseminated human B-cell lymphoma in immunodeficient mice. Clin Cancer Res (2000) 0.84
Emerging combination therapies to overcome resistance in EGFR-driven tumors. Anticancer Drugs (2014) 0.83
The recombinant anti-EGF receptor immunotoxin 425(scFv)-ETA' suppresses growth of a highly metastatic pancreatic carcinoma cell line. Int J Oncol (2003) 0.83
Rapid optical imaging of EGF receptor expression with a single-chain antibody SNAP-tag fusion protein. Eur J Nucl Med Mol Imaging (2010) 0.83
Recombinant immunotoxins and retargeted killer cells: employing engineered antibody fragments for tumor-specific targeting of cytotoxic effectors. Cancer Immunol Immunother (2003) 0.83
SNAP-tag technology: a powerful tool for site specific conjugation of therapeutic and imaging agents. Curr Pharm Des (2013) 0.81
HER/erbB receptors as therapeutic targets of immunotoxins in human rhabdomyosarcoma cells. J Immunother (2002) 0.80
Preclinical testing of erlotinib in a transgenic alveolar rhabdomyosarcoma mouse model. Sarcoma (2011) 0.79
The cytotoxicity of anti-CD22 immunotoxin is enhanced by bryostatin 1 in B-cell lymphomas through CD22 upregulation and PKC-βII depletion. Haematologica (2011) 0.79
Clonal analysis of a human antimouse antibody (HAMA) response. Scand J Immunol (2003) 0.79
Epidermal growth factor receptor expression affects the efficacy of the combined application of saponin and a targeted toxin on human cervical carcinoma cells. Int J Cancer (2010) 0.78
A novel recombinant immunotoxin-based therapy targeting wild-type and mutant EGFR improves survival in murine models of glioblastoma. Oncoimmunology (2013) 0.77
Current state-of-the-art systemic therapy for pediatric soft tissue sarcomas. Curr Oncol Rep (2012) 0.77
SNAP-tag based agents for preclinical in vitro imaging in malignant diseases. Curr Pharm Des (2013) 0.77
Cetuximab promotes anticancer drug toxicity in rhabdomyosarcomas with EGFR amplification in vitro. Oncol Rep (2013) 0.76
Target-specific cytotoxic activity of recombinant immunotoxin scFv(MUC1)-ETA on breast carcinoma cells and primary breast tumors. Mol Cancer Ther (2007) 0.76
A human recombinant autoantibody-based immunotoxin specific for the fetal acetylcholine receptor inhibits rhabdomyosarcoma growth in vitro and in a murine transplantation model. J Biomed Biotechnol (2010) 0.76
A CSPG4-specific immunotoxin kills rhabdomyosarcoma cells and binds to primary tumor tissues. Cancer Lett (2014) 0.76
Targeting the fetal acetylcholine receptor in rhabdomyosarcoma. Expert Opin Ther Targets (2012) 0.75
Technology evaluation: BL22, NCI. Curr Opin Mol Ther (2002) 0.75
Advances in neuropathic pain: diagnosis, mechanisms, and treatment recommendations. Arch Neurol (2003) 3.80
Autophagy promotes MHC class II presentation of peptides from intracellular source proteins. Proc Natl Acad Sci U S A (2005) 3.75
A comprehensive model for the cellular uptake of cationic cell-penetrating peptides. Traffic (2007) 3.01
Impact of myocardial fibrosis in patients with symptomatic severe aortic stenosis. Circulation (2009) 2.88
Low-gradient aortic valve stenosis myocardial fibrosis and its influence on function and outcome. J Am Coll Cardiol (2011) 2.54
Uptake of a fluorescent marker in plant cells is sensitive to brefeldin A and wortmannin. Plant Cell (2002) 1.83
Plant-derived pharmaceuticals--the road forward. Trends Plant Sci (2005) 1.82
Molecular farming in plants: host systems and expression technology. Trends Biotechnol (2003) 1.78
Selective local PMN recruitment by CXCL1 or CXCL2/3 injection does not cause inflammatory pain. J Leukoc Biol (2006) 1.75
Macrophage-expressed IFN-β contributes to apoptotic alveolar epithelial cell injury in severe influenza virus pneumonia. PLoS Pathog (2013) 1.74
Auxin transport inhibitors impair vesicle motility and actin cytoskeleton dynamics in diverse eukaryotes. Proc Natl Acad Sci U S A (2008) 1.74
Combined functional and molecular analysis of tumor cell signaling defines 2 distinct myeloma subgroups: Akt-dependent and Akt-independent multiple myeloma. Blood (2008) 1.69
Factor XIII deficiency causes cardiac rupture, impairs wound healing, and aggravates cardiac remodeling in mice with myocardial infarction. Circulation (2006) 1.60
Fusion proteins comprising a Fusarium-specific antibody linked to antifungal peptides protect plants against a fungal pathogen. Nat Biotechnol (2004) 1.59
Emphysematous gastritis caused by Sarcina ventriculi. Gastrointest Endosc (2010) 1.54
CXCR1/2 ligands induce p38 MAPK-dependent translocation and release of opioid peptides from primary granules in vitro and in vivo. Brain Behav Immun (2007) 1.48
p53 family members in myogenic differentiation and rhabdomyosarcoma development. Cancer Cell (2006) 1.47
Molecular farming for new drugs and vaccines. Current perspectives on the production of pharmaceuticals in transgenic plants. EMBO Rep (2005) 1.45
Intra-articular morphine for inflammatory pain. Reg Anesth Pain Med (2006) 1.41
Chronic morphine use does not induce peripheral tolerance in a rat model of inflammatory pain. J Clin Invest (2008) 1.27
Plant cell cultures for the production of recombinant proteins. Nat Biotechnol (2004) 1.27
Sowing the seeds of success: pharmaceutical proteins from plants. Curr Opin Biotechnol (2005) 1.26
A recombinant trispecific single-chain Fv derivative directed against CD123 and CD33 mediates effective elimination of acute myeloid leukaemia cells by dual targeting. Br J Haematol (2010) 1.25
Cell-specific induction of apoptosis by rationally designed bivalent aptamer-siRNA transcripts silencing eukaryotic elongation factor 2. Curr Cancer Drug Targets (2008) 1.24
Unexpected deposition patterns of recombinant proteins in post-endoplasmic reticulum compartments of wheat endosperm. Plant Physiol (2004) 1.22
Simultaneous occurrence of Hodgkin's lymphoma and eosinophilic granuloma: a potential pitfall in positron emission tomography imaging. Clin Lymphoma (2002) 1.21
Chronic nonbacterial osteomyelitis in childhood: prospective follow-up during the first year of anti-inflammatory treatment. Arthritis Res Ther (2010) 1.20
Genetic determinants of Pseudomonas aeruginosa biofilm establishment. Microbiology (2009) 1.19
Preliminary X-ray analysis of a human V(H) fragment at 1.8 A resolution. Acta Crystallogr D Biol Crystallogr (2004) 1.18
Evolution of a regulatory framework for pharmaceuticals derived from genetically modified plants. Trends Biotechnol (2008) 1.18
Transgenic plants in the biopharmaceutical market. Expert Opin Emerg Drugs (2005) 1.18
Endosperm-specific co-expression of recombinant soybean ferritin and Aspergillus phytase in maize results in significant increases in the levels of bioavailable iron. Plant Mol Biol (2005) 1.17
Mutated RAS and constitutively activated Akt delineate distinct oncogenic pathways, which independently contribute to multiple myeloma cell survival. Blood (2010) 1.16
A case of a diffuse large B-cell lymphoma of plasmablastic type associated with the t(2;5)(p23;q35) chromosome translocation. Am J Surg Pathol (2003) 1.15
The structure of the dizinc subclass B2 metallo-beta-lactamase CphA reveals that the second inhibitory zinc ion binds in the histidine site. Antimicrob Agents Chemother (2009) 1.14
Recombinant antibody 2G12 produced in maize endosperm efficiently neutralizes HIV-1 and contains predominantly single-GlcNAc N-glycans. Plant Biotechnol J (2007) 1.13
Polyphenoloxidase silencing affects latex coagulation in Taraxacum species. Plant Physiol (2009) 1.11
Mu-opioid receptor activation modulates transient receptor potential vanilloid 1 (TRPV1) currents in sensory neurons in a model of inflammatory pain. Mol Pharmacol (2006) 1.11
Subcellular pathways of beta-endorphin synthesis, processing, and release from immunocytes in inflammatory pain. Endocrinology (2003) 1.10
Altered cell-mediated immunity and increased postoperative infection rate in long-term alcoholic patients. Anesthesiology (2004) 1.09
Pain control by CXCR2 ligands through Ca2+-regulated release of opioid peptides from polymorphonuclear cells. FASEB J (2006) 1.09
Potato virus X as a novel platform for potential biomedical applications. Nano Lett (2010) 1.08
Relative contribution of peripheral versus central opioid receptors to antinociception. Brain Res (2007) 1.07
Spatial and temporal regulation of the forisome gene for1 in the phloem during plant development. Plant Mol Biol (2007) 1.06
An unusual internal ribosomal entry site of inverted symmetry directs expression of a potato leafroll polerovirus replication-associated protein. Proc Natl Acad Sci U S A (2003) 1.06
Different mechanisms of intrinsic pain inhibition in early and late inflammation. J Neuroimmunol (2003) 1.06
Biochemical and functional characterization of anti-HIV antibody-ELP fusion proteins from transgenic plants. Plant Biotechnol J (2008) 1.05
The potential of plant virus vectors for vaccine production. Drugs R D (2006) 1.03
Granzyme B-H22(scFv), a human immunotoxin targeting CD64 in acute myeloid leukemia of monocytic subtypes. Mol Cancer Ther (2008) 1.03
Perforin-like protein PPLP2 permeabilizes the red blood cell membrane during egress of Plasmodium falciparum gametocytes. Cell Microbiol (2014) 1.02
Cationic cell-penetrating peptides interfere with TNF signalling by induction of TNF receptor internalization. J Cell Sci (2005) 1.01
Plant molecular pharming for the treatment of chronic and infectious diseases. Annu Rev Plant Biol (2014) 1.00
Molecular farming of pharmaceutical proteins using plant suspension cell and tissue cultures. Curr Pharm Des (2013) 1.00
Characterization of rubber particles and rubber chain elongation in Taraxacum koksaghyz. BMC Biochem (2010) 1.00
Cellulases for biomass degradation: comparing recombinant cellulase expression platforms. Trends Biotechnol (2013) 0.99
Development of viral nanoparticles for efficient intracellular delivery. Nanoscale (2012) 0.99
Control of inflammatory pain by chemokine-mediated recruitment of opioid-containing polymorphonuclear cells. Pain (2004) 0.99
Effective elimination of acute myeloid leukemic cells by recombinant bispecific antibody derivatives directed against CD33 and CD16. J Immunother (2010) 0.99
Immunohistochemical localization of endomorphin-1 and endomorphin-2 in immune cells and spinal cord in a model of inflammatory pain. J Neuroimmunol (2002) 0.99
Influence of elastin-like peptide fusions on the quantity and quality of a tobacco-derived human immunodeficiency virus-neutralizing antibody. Plant Biotechnol J (2009) 0.98
Rapid high-level production of functional HIV broadly neutralizing monoclonal antibodies in transient plant expression systems. PLoS One (2013) 0.98
Rapid transient production in plants by replicating and non-replicating vectors yields high quality functional anti-HIV antibody. PLoS One (2010) 0.98
Proteins from the FLOWERING LOCUS T-like subclade of the PEBP family act antagonistically to regulate floral initiation in tobacco. Plant J (2012) 0.97
Recombinant anti-hCG antibodies retained in the endoplasmic reticulum of transformed plants lack core-xylose and core-alpha(1,3)-fucose residues. Plant Biotechnol J (2004) 0.97
Endothelin potentiates TRPV1 via ETA receptor-mediated activation of protein kinase C. Mol Pain (2007) 0.97
Opportunities for recombinant antigen and antibody expression in transgenic plants--technology assessment. Vaccine (2005) 0.97
Functional analysis of the broadly neutralizing human anti-HIV-1 antibody 2F5 produced in transgenic BY-2 suspension cultures. FASEB J (2007) 0.97
Monoclonal tobacco cell lines with enhanced recombinant protein yields can be generated from heterogeneous cell suspension cultures by flow sorting. Plant Biotechnol J (2012) 0.97
Mobilization of opioid-containing polymorphonuclear cells by hematopoietic growth factors and influence on inflammatory pain. Anesthesiology (2004) 0.97
Design of protein membrane interaction inhibitors by virtual ligand screening, proof of concept with the C2 domain of factor V. Proc Natl Acad Sci U S A (2007) 0.96
Secretion of functional anti-CD30-angiogenin immunotoxins into the supernatant of transfected 293T-cells. Protein Expr Purif (2003) 0.96
Tissue monocytes/macrophages in inflammation: hyperalgesia versus opioid-mediated peripheral antinociception. Anesthesiology (2004) 0.96
Viroid-induced RNA silencing of GFP-viroid fusion transgenes does not induce extensive spreading of methylation or transitive silencing. Plant J (2004) 0.96
The intracellular fate of a recombinant protein is tissue dependent. Plant Physiol (2006) 0.96
Plantibodies: applications, advantages and bottlenecks. Curr Opin Biotechnol (2002) 0.96
Peripheral antinociceptive effects of exogenous and immune cell-derived endomorphins in prolonged inflammatory pain. J Neurosci (2006) 0.96
A single-chain triplebody with specificity for CD19 and CD33 mediates effective lysis of mixed lineage leukemia cells by dual targeting. MAbs (2011) 0.95
Malignant melanoma with metastatic rhabdomyosarcomatoid transdifferentiation. N Engl J Med (2008) 0.95
A CD14 domain with lipopolysaccharide-binding and -neutralizing activity. Chembiochem (2006) 0.95
Mycobacteria attenuate nociceptive responses by formyl peptide receptor triggered opioid peptide release from neutrophils. PLoS Pathog (2009) 0.95
Sympathetic activation triggers endogenous opioid release and analgesia within peripheral inflamed tissue. Eur J Neurosci (2004) 0.95
Production of Desmodus rotundus salivary plasminogen activator alpha1 (DSPAalpha1) in tobacco is hampered by proteolysis. Biotechnol Bioeng (2005) 0.95
With or without sugar? (A)glycosylation of therapeutic antibodies. Mol Biotechnol (2013) 0.95
Opioid receptors and opioid peptide-producing leukocytes in inflammatory pain--basic and therapeutic aspects. Brain Behav Immun (2009) 0.95
Restrictive cardiomyopathy in a patient with primary hyperoxaluria type II. Clin Res Cardiol (2006) 0.94
The EphA3 receptor is expressed in a subset of rhabdomyosarcoma cell lines and suppresses cell adhesion and migration. J Cell Biochem (2008) 0.94
Harmonine, a defence compound from the harlequin ladybird, inhibits mycobacterial growth and demonstrates multi-stage antimalarial activity. Biol Lett (2011) 0.94
Characterization of mu opioid receptor binding and G protein coupling in rat hypothalamus, spinal cord, and primary afferent neurons during inflammatory pain. J Pharmacol Exp Ther (2003) 0.94
Detailed functional characterization of glycosylated and nonglycosylated variants of malaria vaccine candidate PfAMA1 produced in Nicotiana benthamiana and analysis of growth inhibitory responses in rabbits. Plant Biotechnol J (2014) 0.94
Small cleavable adapters enhance the specific cytotoxicity of a humanized immunotoxin directed against CD64-positive cells. J Immunother (2008) 0.94
Beta-endorphin, Met-enkephalin and corresponding opioid receptors within synovium of patients with joint trauma, osteoarthritis and rheumatoid arthritis. Ann Rheum Dis (2007) 0.93
Leukocyte-derived opioid peptides and inhibition of pain. J Neuroimmune Pharmacol (2006) 0.93
A recombinant multimeric immunoglobulin expressed in rice shows assembly-dependent subcellular localization in endosperm cells. Plant Biotechnol J (2005) 0.93
Site-specific, covalent labeling of recombinant antibody fragments via fusion to an engineered version of 6-O-alkylguanine DNA alkyltransferase. Bioconjug Chem (2009) 0.93
Malaria parasites co-opt human factor H to prevent complement-mediated lysis in the mosquito midgut. Cell Host Microbe (2013) 0.93
Immune mechanisms in pain control. Anesth Analg (2002) 0.92